BEACON introduces another promising kinase inhibitor, Baricitinib, under the brand name of Baricinix for global market.
Baricinix is an anti-rheumatic drug. It is used in-
The treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to or who are intolerant to one or more disease odifying anti rheumatic drugs.
Baricitinib may be used as monotherapy or in combination with Methotrexate.
Baricinix is an oral tablet preparation which is available in the strengths of 2 mg and 4 mg.
To know more visit our product website : www.baricinix.com